- GSK plans to invest €250 million in its Currabinny, Ireland site over the next five years.
- The investment supports production of lapatinib, the active ingredient in Tykerb.
- Tykerb, combined with Xeloda, was approved by the FDA in March 2007 for advanced breast cancer.
- The investment will create up to 150 new jobs at the site, which employs over 600 people.
Investment Overview
GlaxoSmithKline (GSK) plans to invest €250 million ($334 million) in its production site at Currabinny, Ireland over the next five years. This significant investment aims to enhance the facility's capabilities and support the production of key pharmaceutical ingredients.
Production Focus
The investment will specifically support the production of lapatinib, the active ingredient in GSK’s Tykerb, an oral treatment for advanced breast cancer. Tykerb, in combination with Roche’s Xeloda (capecitabine), was approved by the US Food and Drug Administration (FDA) in March 2007 for treating advanced or metastatic breast cancer.
Site Significance
GSK Cork, where the Currabinny site is located, is a strategic global new product introduction site within GSK. The facility, established in 1975, currently employs more than 600 people and is responsible for manufacturing the active ingredients of various medicinal compounds.
Job Creation
According to IDA Ireland, the investment will create up to 150 new high-level positions at the Currabinny site. IDA Ireland is an Irish government agency tasked with attracting new investment from overseas in the manufacturing and internationally traded services sectors.
